Alzheon Revenue and Competitors
Estimated Revenue & Valuation
- Alzheon's estimated annual revenue is currently $3.2M per year.
- Alzheon's estimated revenue per employee is $106,400
- Alzheon's total funding is $128M.
- Alzheon's current valuation is $1.3B.
Employee Data
- Alzheon has 30 Employees.
- Alzheon grew their employee count by 30% last year.
Alzheon's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Founder, President & CEO | Reveal Email/Phone |
2 | CSO | Reveal Email/Phone |
3 | Chief Staff | Reveal Email/Phone |
4 | VP Program and Portfolio Management | Reveal Email/Phone |
5 | VP Clinical Development | Reveal Email/Phone |
6 | VP Clinical Development and Medical Affairs | Reveal Email/Phone |
7 | VP Brand Marketing | Reveal Email/Phone |
8 | VP Market Access | Reveal Email/Phone |
9 | Chief Financial Officer | Reveal Email/Phone |
10 | Chief Medical Officer | Reveal Email/Phone |
Alzheon Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $14.1M | 101 | 5% | N/A | N/A |
#2 | $212.8M | 1063 | 5% | $65M | N/A |
#3 | $1M | 12 | N/A | N/A | N/A |
#4 | $35.6M | 231 | 6% | N/A | N/A |
#5 | $45M | 299 | -4% | $102.6M | N/A |
#6 | $12.3M | 88 | 13% | N/A | N/A |
#7 | $2.5M | 26 | N/A | N/A | N/A |
#8 | $27.2M | 181 | -36% | $162.2M | N/A |
#9 | $0.4M | 11 | -31% | $11.4M | N/A |
#10 | $1.2M | 14 | -33% | N/A | N/A |
What Is Alzheon?
Alzheon, Inc. is committed to developing innovative medicines by directly addressing the underlying pathology of devastating neurodegenerative disorders. Our lead Alzheimer’s clinical candidate, ALZ-801, is a Phase 3-ready, first-in-class, small molecule oral inhibitor of amyloid aggregation and neurotoxicity – hallmarks of Alzheimer’s disease. ALZ-801 is a novel prodrug that builds on the safety and efficacy profile of the active compound tramiprosate, which has been evaluated in clinical trials involving over 2,000 Alzheimer’s patients. Our clinical expertise and technology platform is focused on developing drug candidates using a precision medicine approach based on individual genetic and biological information to advance therapies with the greatest impact for patients. www.alzheon.com
keywords:N/A
$128M
Total Funding
30
Number of Employees
$3.2M
Revenue (est)
30%
Employee Growth %
$1.3B
Valuation
N/A
Accelerator
Alzheon News
Money on the Move: Tessera, Unlearn.AI, Blue Spark, Alzheon and Trevana. Published: Apr 20, 2022 By Hannah Chudleigh. Funding. The major pharma and biotech...
Alzheon Announces Closing of Oversubscribed $50 Million Series D Financing Round to Accelerate Completion of APOLLOE4 Phase 3 Trial and...
Biotechnology company Alzheon Inc. has raised $50 million in new venture capital to complete clinical trials of a potential oral medication...
Alzheon, Inc., a clinical-stage biopharmaceutical company focused on developing new medicines for patients suffering from Alzheimer’s disease (AD) and other neurodegenerative disorders, today announced the dosing of the first patient in its APOLLOE4 Phase 3 study evaluating the efficacy and safe ...
A company based just outside Boston is joining the parade to the public markets, hoping to raise $80.5 million to develop an Alzheimer’s drug that’s a true Hail Mary, considering the field’s recent implosions. Martin Tolar The drugmaker, Alzheon, filed a notice with the S ...
Other Companies in
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $5.9M | 30 | -9% | N/A |
#2 | $5.9M | 30 | 7% | N/A |
#3 | $5.9M | 30 | 0% | N/A |
#4 | $2.4M | 30 | 30% | N/A |
#5 | $5M | 30 | -6% | N/A |